Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market, By Product Type (MIGS Shunt, MIGS Stent, Trabectome, Kahook Dual Blade, Tube Shunt, Micro-Implants, Micro Catheters and Others), Target (Trabecular Meshwork, Suprachoroidal Space, Subconjunctival Filtration, Reducing Aqueous Production and Others), Surgery Type (Glaucoma in Conjunction with Cataract, Stand-Alone Glaucoma), Glaucoma Type (Open Angle Glaucoma, Acute Angle-Closure Glaucoma, Normal-Tension Glaucoma, Secondary Glaucoma, Pigmentary Glaucoma and Congenital Glaucoma), End User (Hospital's Outpatients Department (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2030.
Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market Analysis and Insights
Micro invasive glaucoma surgery (MIGS) is used to treat open-angle glaucoma. Initially, to treat OAG, medication was given that reduced aqueous humor production or increased aqueous humor outflow. For mild to moderate OAG, traditionally, pharmacologic and laser treatment was performed. With the coming of micro invasive glaucoma surgery (MIGS) procedures, new options were created for those not fit for conventional surgery. An increase in the population of geriatrics and increasing government initiatives for the prevention of blindness are expected to boost the market. Rapid transition from glaucoma medication to minimally invasive glaucoma surgeries might be creating opportunities for the manufacturer of MIGS devices.
Data Bridge Market Research analyzes that the Europe micro invasive glaucoma surgery (MIGS) devices market is expected to reach the value of USD 1,738.15 million by 2030, at a CAGR of 29.7% during the forecast period 2023-2030. MIGS shunt accounts for the largest product type segment in the market due to growing demand of minimally invasive surgical devices.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (MIGS Shunt, MIGS Stent, Trabectome, Kahook Dual Blade, Tube Shunt, Micro-Implants, Micro Catheters and Others), Target (Trabecular Meshwork, Suprachoroidal Space, Subconjunctival Filtration, Reducing Aqueous Production and Others), Surgery Type (Glaucoma in Conjunction with Cataract, Stand-Alone Glaucoma), Glaucoma Type (Open Angle Glaucoma, Acute Angle-Closure Glaucoma, Normal-Tension Glaucoma, Secondary Glaucoma, Pigmentary Glaucoma and Congenital Glaucoma), End User (Hospital's Outpatients Department (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
Germany, U.K., France, Italy, Russia, Spain, Turkey, Switzerland, Netherlands, Belgium, Denmark, Poland, Sweden, Norway, Finland and Rest of Europe
|
|
Market Players Covered
|
Glaukos corporation, AbbVie Inc., Alcon, Johnson & Johnson Vision Care Inc., Sight sciences, Inc., Santen Pharmaceutical Co., Ltd, iSTAR Medical, BVI, Nova Eye Medical, Lumenis Be Ltd, Inami & Co., Ltd, Oertli Instrumente AG, Lumibird
|
Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market Definition
MIGS stands for micro invasive glaucoma surgery, which helps treat glaucoma. It is a breakthrough technology in the treatment of mild to moderate glaucoma. It is an alternative to the medications given earlier, and it also prevents the complications of conventional surgery. These procedures are used to lower the intra-ocular pressure of the eye to avoid damage to the optic nerve. These procedures are safer and have a very rapid recovery time compared to conventional surgery. The various MIGS devices implanted are shunts and stents to lower the IOP.
The growing incidences of eye diseases, rising demand for micro invasive glaucoma surgery, rising number of players in the market, and novel product launches are also propelling the growth of the Europe micro invasive surgery device market (MIGS).
Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growth in Popularity of Minimally Invasive Surgery
Glaucoma is the second most common cause of blindness. According to WHO, 4.5 million people are blind because of glaucoma. The only effective treatment of glaucoma is to lower intra-ocular pressure so that there is no damage to the optic nerve. Earlier, there were only three ways to treat glaucoma; medications, laser therapy, and in severe cases, incisional surgeries. The medicines have some drawbacks, like patient adherence and ocular toxicity. Also, these are costly and are only available to some in developing countries. Laser therapies, though, are non-invasive. They lose their effectiveness over the period. Incisional surgeries are the most effective treatment to lower intraocular pressure. Still, they can fail due to scarring, decreased quality of life due to bleb-related foreign body sensation, induced astigmatism, and secondary cataracts.
MIGS provide provides safer, less invasive means of reducing intraocular pressure. Also, they reduce the dependencies on medication. They have quicker recovery time and modest results compared to incisional surgeries. Hence, surgeons and patients are increasingly adopting these micro-invasive surgeries. Therefore, the growing popularity of minimally invasive surgery is expected to drive the market growth.
- Rise in Incidence of Glaucoma
The cause of irreversible global blindness is majorly glaucoma. A glaucoma is a group of eye disorders that have very little to no symptoms in the initial stage but afterward lead to damage of optic nerves, which can lead to vision loss or blindness. The prevalence of glaucoma has been increasing.
Improving the quality of life is instrumental to reducing the burden of glaucoma, as it has several severe risk factors. It is necessary to shift to revolutionary techniques like micro invasive glaucoma surgery to overcome it at an early stage. Therefore this creates a demand for MIGS devices; hence an increasing incidence of glaucoma is expected to act as a driver for the market.
Opportunity
-
Introduction of Technological Advanced Product
Glaucoma is a severe eye disease that can lead to vision loss if not controlled. It generally does not lead to blindness as it can be controlled by modern treatment and many options for preventing further damage. With the increased scientific developments, there has been a revolutionary change in the treatment of glaucoma. With the advent of micro-invasive glaucoma surgery, there is a paradigm shift in medicine as it can help in the treatment of glaucoma at an early stage and avoid the dependency on filtration surgeries like trabeculectomy. This also overcomes the risks associated with these incisional surgeries. There are various advancements in the treatment of glaucoma with MIGS.
These new technologies are safer, and they give modest to good results. Therefore these are being increasingly adopted by patients and surgeons. This creates an opportunity for manufacturers to produce more technologically advanced devices. Hence, introducing technologically advanced products might act as an opportunity for the market.
Restraints/ Challenges
-
Inadequate Reimbursement Scenario
Vision is on the line with glaucoma; many people continue to lose sight daily with this disease. Patients with mild to moderate glaucoma received medical therapy conventionally, and the surgical options were confined to people with severe glaucoma. However, there is a paradigm shift in the treatment of glaucoma with the introduction of MIGS devices. Advanced glaucoma damage can be avoided by performing micro invasive glaucoma surgery at an early stage.
The surgeons don’t prefer to use MIGS devices because the reimbursements are so low. When the people are not paid for it, they stop using it, and ultimately its production stops. Although MIGS devices are revolutionizing the treatment of glaucoma, the approval and payment by insurance companies of these devices are seen as an obstacle. Therefore, poor reimbursements are expected to be considered a restraint for the market.
- Lack of Skilled Professionals with Adequate Knowledge
Intra-ocular surgery is a very complex task as the work has to be done in smaller spaces adjacent to susceptible structures where any mistake can lead to permanent vision loss. This makes the presence of skilled professionals a necessity for the surgery. Performing MIGS requires an even higher skill level because it involves the treatment, working in smaller, more sensitive spaces within the eye, and learning a new proprioceptive skill, namely intraoperative surgical gonioscopic viewing of the angle. Though the presence of skilled professionals is highly required, there is an acute shortage of trained surgeons in developing countries.
Even more, scarcity can be observed in professionals specialized in ophthalmological surgery across the globe, making it a severe problem in treating glaucoma. As the numbers of surgeons are meager, the number of surgical procedures will be deficient; therefore, this is seen as an obstacle. Thus, a high level of market dependency on the availability of skilled professionals with adequate knowledge might challenge the market.
Recent Development
- In February 2022, Santen is launching an innovative, interactive medical education platform for healthcare professionals (HCPs). It gives ophthalmologists access to high-quality, personalized learning at their own pace. This will help increase awareness amongst healthcare professionals and lead to better treatment and growth for the company
Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market Scope
The Europe micro invasive glaucoma surgery (MIGS) devices market is categorized into six segments by product type, target, surgery type, glaucoma type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product Type
- Migs Stents
- Migs Shunts
- Trabectome
- Kahook Dual Blade
- Tube Shunt
- Micro Implants
- Micro Catheters
- Others
On the basis of product type, the Europe micro invasive glaucoma surgery (MIGS) devices market is segmented into MIGS shunts, MIGS stents, trabectome, kahook dual blade, tube shunt, micro implants, micro catheters and others.
Target
- Trabecular Meshwork
- Suprachoroidal Space
- Subconjunctival Filtration
- Reducing aqueous Production
- Others
On the basis of target, the europe micro invasive glaucoma surgery (migs) devices market is segmented into the trabecular meshwork, suprachoroidal space, subconjunctival filtration, reducing aqueous production and others.
Surgery Type
- Glaucoma in Conjunction with Cataract
- Stand-alone Glaucoma
On the basis of surgery type, the europe micro invasive glaucoma surgery (MIGS) devices market is segmented into glaucoma in conjunction with cataract and stand-alone glaucoma.
Glaucoma Type
- Open- angle Glaucoma
- Acute angle- closure Glaucoma
- Normal – tension Glaucoma
- Secondary Glaucoma
- Pigmentary Glaucoma
- Congenital Glaucoma
On the basis of glaucoma type, the europe micro invasive glaucoma surgery (migs) devices market is segmented into open angle glaucoma, acute angle closure glaucoma, normal tension glaucoma, secondary glaucoma, pigmentary glaucoma and congenital glaucoma.
End User
- Hospital Outpatient Departments (HOPD)
- Ophthalmology Clinics
- Ambulatory Surgery Centers (ASCS)
- Others
On the basis of end-user, the europe micro invasive glaucoma surgery (MIGS) devices market is segmented into hospital outpatient departments (HOPD), ophthalmology clinics, ambulatory surgery centers (ASCS), and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the europe micro invasive glaucoma surgery (MIGS) devices market is segmented into direct tender and retail sales.
Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market Regional Analysis/Insights
The Europe micro invasive glaucoma surgery (MIGS) devices market is categorized into six segments by product type, target, surgery type, glaucoma type, end user, and distribution channel.
The countries covered in this market report Germany, U.K., France, Italy, Russia, Spain, Turkey, Switzerland, Netherlands, Belgium, Denmark, Poland, Sweden, Norway, Finland and the rest of Europe.
Germany is dominating due to rise in prevalence of glaucoma or other related issues among the population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market Share Analysis
Europe micro invasive glaucoma surgery (MIGS) devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R and D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Europe micro invasive glaucoma surgery (MIGS) devices market.
Some of the major players operating in the Europe micro invasive glaucoma surgery (MIGS) devices market are Glaukos corporation, AbbVie Inc., Alcon, Johnson & Johnson Vision Care Inc., Sight sciences, Inc., Santen Pharmaceutical Co., Ltd, iSTAR Medical, BVI, Nova Eye Medical, Lumenis Be Ltd, Inami & Co., Ltd, Oertli Instrumente AG, Lumibird and among others.
SKU-